Thursday, February 02, 2012

Understanding the Impact of Drug Induced Liver Injury on Drug Development

Thought Leader: Steve Lobel, PhD, D-ABMLI, MBA, FACB, Vice-president Global Laboratory Operations, PPD

In this episode, Dr. Lobel talks about Drug-induced liver injury, also known as DILI. We'll cover what DILI is, how it is identified, and its effects on the clinical development process. At the end of this podcast, you'll learn where you can download a related white paper on this topic.

Play Podcast

For more information on how you can be featured in a podcast, contact Dan Limbach at or call him at (847) 594-0157.

No comments: